Compare IBOC & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBOC | TMDX |
|---|---|---|
| Founded | 1966 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | 1995 | 2019 |
| Metric | IBOC | TMDX |
|---|---|---|
| Price | $66.17 | $130.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $85.00 | ★ $152.33 |
| AVG Volume (30 Days) | 260.6K | ★ 788.7K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | 0.76 | ★ 382.18 |
| EPS | ★ 6.62 | 4.87 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | N/A | $24.12 |
| Revenue Next Year | N/A | $18.69 |
| P/E Ratio | ★ $10.05 | $26.69 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $54.11 | $62.42 |
| 52 Week High | $75.44 | $156.00 |
| Indicator | IBOC | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 36.64 | 43.48 |
| Support Level | $63.73 | $124.45 |
| Resistance Level | $68.88 | $142.44 |
| Average True Range (ATR) | 2.33 | 8.55 |
| MACD | -0.51 | -0.60 |
| Stochastic Oscillator | 21.55 | 24.47 |
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.